Details

Autor(en) / Beteiligte

• Crean, C.S
• Ratner, P.H
• Widmann, M
• Schaberg, A
• Kellerman, D

Titel

Pharmacokinetic Model of Epinastine, an H1 Antagonist, after Nasal Administration

Ist Teil von

• Journal of allergy and clinical immunology, 2008-02, Vol.121 (2), p.S50-S50

Ort / Verlag

St. Louis: Elsevier Limited

Erscheinungsjahr

2008

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Conclusions A PK model for epinastine was established and confirms that systemic exposure from intranasal dosages at 0.14 mg and 0.28 mg is linear, reaches steady state by Day 3 and based on Cmax and AUC is minimally 58-fold below the 20 mg oral dose modeling. [...]the effectiveness of epinastine delivered as a nasal solution is due to local activity and not systemic exposure.